Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity, Morbid | 5 | 2022 | 58 | 2.210 |
Why?
|
| Bariatric Surgery | 4 | 2022 | 44 | 1.640 |
Why?
|
| Gastric Bypass | 2 | 2021 | 19 | 1.320 |
Why?
|
| Splenectomy | 2 | 2020 | 44 | 1.270 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2020 | 94 | 1.200 |
Why?
|
| Bariatrics | 1 | 2022 | 1 | 0.750 |
Why?
|
| Frailty | 1 | 2022 | 24 | 0.720 |
Why?
|
| Hypoglycemia | 1 | 2021 | 34 | 0.680 |
Why?
|
| Certification | 1 | 2016 | 16 | 0.500 |
Why?
|
| Educational Measurement | 1 | 2016 | 137 | 0.460 |
Why?
|
| General Surgery | 1 | 2016 | 63 | 0.460 |
Why?
|
| Retrospective Studies | 8 | 2022 | 2638 | 0.390 |
Why?
|
| Internship and Residency | 1 | 2016 | 250 | 0.390 |
Why?
|
| Humans | 16 | 2022 | 28912 | 0.290 |
Why?
|
| Adult | 9 | 2021 | 8038 | 0.240 |
Why?
|
| Postoperative Complications | 3 | 2022 | 634 | 0.220 |
Why?
|
| Female | 11 | 2022 | 15651 | 0.190 |
Why?
|
| Male | 10 | 2021 | 13947 | 0.190 |
Why?
|
| Feeding and Eating Disorders | 1 | 2022 | 15 | 0.190 |
Why?
|
| Body Image | 1 | 2022 | 20 | 0.190 |
Why?
|
| Cetuximab | 1 | 2021 | 22 | 0.180 |
Why?
|
| Camptothecin | 1 | 2021 | 16 | 0.180 |
Why?
|
| Appendiceal Neoplasms | 1 | 2021 | 5 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2022 | 109 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2021 | 2426 | 0.170 |
Why?
|
| Risk Factors | 3 | 2021 | 2129 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 33 | 0.170 |
Why?
|
| Length of Stay | 1 | 2022 | 245 | 0.170 |
Why?
|
| Bevacizumab | 1 | 2021 | 106 | 0.170 |
Why?
|
| Middle Aged | 8 | 2021 | 7420 | 0.170 |
Why?
|
| Spleen | 1 | 2020 | 114 | 0.160 |
Why?
|
| Aged | 6 | 2021 | 5604 | 0.160 |
Why?
|
| Recurrence | 1 | 2020 | 327 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 429 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 142 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2020 | 274 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 136 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 75 | 0.150 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 9 | 0.140 |
Why?
|
| Pancreatic Fistula | 1 | 2018 | 14 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2018 | 42 | 0.140 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 38 | 0.140 |
Why?
|
| Laparoscopy | 1 | 2019 | 156 | 0.140 |
Why?
|
| Prospective Studies | 1 | 2021 | 1280 | 0.130 |
Why?
|
| Mutation | 1 | 2021 | 868 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 433 | 0.130 |
Why?
|
| Wisconsin | 1 | 2016 | 9 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 146 | 0.120 |
Why?
|
| Esophagectomy | 1 | 2016 | 10 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 33 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2016 | 174 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2016 | 103 | 0.120 |
Why?
|
| Esophagus | 1 | 2016 | 72 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2015 | 98 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2016 | 239 | 0.110 |
Why?
|
| Oxytocin | 1 | 2014 | 6 | 0.110 |
Why?
|
| Facial Expression | 1 | 2014 | 17 | 0.110 |
Why?
|
| Uncertainty | 1 | 2014 | 25 | 0.110 |
Why?
|
| Interpersonal Relations | 1 | 2014 | 65 | 0.100 |
Why?
|
| Love | 1 | 2013 | 3 | 0.100 |
Why?
|
| Meditation | 1 | 2013 | 4 | 0.100 |
Why?
|
| Telomere | 1 | 2013 | 36 | 0.100 |
Why?
|
| Emotions | 1 | 2014 | 138 | 0.100 |
Why?
|
| Decision Making | 1 | 2014 | 179 | 0.090 |
Why?
|
| Sex Factors | 3 | 2021 | 469 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 548 | 0.090 |
Why?
|
| Enbucrilate | 1 | 2009 | 1 | 0.080 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2009 | 16 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 40 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 48 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 811 | 0.060 |
Why?
|
| Drive | 1 | 2022 | 3 | 0.050 |
Why?
|
| Thinness | 1 | 2022 | 21 | 0.050 |
Why?
|
| Fear | 1 | 2022 | 60 | 0.050 |
Why?
|
| Leucovorin | 1 | 2021 | 19 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2021 | 58 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 62 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 105 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 42 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 194 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 226 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 302 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 270 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 38 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 415 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 631 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 69 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 110 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 126 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 190 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 236 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 288 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2227 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 391 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 480 | 0.030 |
Why?
|
| Anger | 1 | 2014 | 15 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 165 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 397 | 0.030 |
Why?
|
| Affect | 1 | 2014 | 85 | 0.030 |
Why?
|
| Perception | 1 | 2014 | 90 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2065 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 300 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 58 | 0.020 |
Why?
|
| Leukocytes | 1 | 2013 | 72 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 270 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 378 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 412 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 118 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 485 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 1032 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 1174 | 0.010 |
Why?
|
| Child | 1 | 2009 | 2292 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 2841 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 3199 | 0.010 |
Why?
|